Chapter 33 — Anti-Cancer Drugs Part I: Pharmacology — Module 4 — Topoisomerase Inhibitors and Antitumor Antibiotics
1. As a replication fork or RNA polymerase moves along DNA, the double helix ahead becomes overwound, building up torsional strain that would stall the process. A family of nuclear enzymes called topoisomerases solves this problem. What do topoisomerases do to relieve this strain?
A) They unwind the entire double helix into two permanently separate single strands that are later rejoined by a different enzyme
B) They make transient cuts in the DNA, allow the strands to rotate or pass through to release the strain, and then reseal the cuts
C) They add methyl groups to the DNA backbone to loosen the coiling without cutting any strands
D) They permanently remove a segment of DNA ahead of the fork and replace it with a relaxed segment
E) They coat the DNA with protective proteins that physically prevent any supercoiling from forming
ANSWER: B
Rationale:
Topoisomerases relieve torsional strain by transiently cleaving the DNA backbone, permitting controlled rotation (Topo I) or strand passage (Topo II), and then religating the cut so that intact, relaxed DNA is released. This transient cut-and-reseal cycle is the exact step that topoisomerase-inhibiting anticancer drugs exploit: by trapping the enzyme on the DNA at the moment it is cut, the drugs convert a routine housekeeping reaction into lethal DNA damage.
Option A: Option A is incorrect because topoisomerases do not separate the helix into two permanently free single strands; that bulk unwinding is the job of helicases, and the topoisomerase cut is transient, not a permanent separation.
Option C: Option C is incorrect because topoisomerases do not chemically modify the DNA backbone with methyl groups; methylation is an epigenetic modification carried out by DNA methyltransferases and has nothing to do with relieving supercoiling.
Option D: Option D is incorrect because topoisomerases do not excise and replace DNA segments; segment excision and replacement describes nucleotide excision repair, not supercoil relief.
Option E: Option E is incorrect because coating DNA with proteins does not relieve existing torsional strain, and no such mechanism is how supercoiling is resolved; the strain must be released by cutting, not prevented by shielding.
2. The camptothecin class of anticancer drugs includes irinotecan and topotecan. These drugs work by interfering with one specific topoisomerase enzyme. Which enzyme do the camptothecins target, and what kind of cut does that enzyme normally make in DNA?
A) Topoisomerase II, which makes a double-strand break in DNA
B) DNA polymerase, which adds new nucleotides during replication
C) DNA gyrase, a bacterial-only enzyme with no human counterpart
D) Topoisomerase I, which makes a transient single-strand cut (nick) in DNA
E) Helicase, which separates the two strands of the double helix
ANSWER: D
Rationale:
Camptothecins target topoisomerase I (Topo I), the enzyme that relieves supercoiling by making a transient single-strand cut (a nick) in one strand of the double helix, allowing the intact strand to rotate and release torsional strain before the nick is resealed. The drug binds at the enzyme-DNA interface and stabilizes the nicked intermediate so it cannot reseal, which becomes lethal when a replication fork collides with the trapped complex.
Option A: Option A is incorrect because topoisomerase II, which makes a double-strand break, is the target of the epipodophyllotoxins (etoposide) and anthracyclines (doxorubicin), not the camptothecins.
Option B: Option B is incorrect because DNA polymerase adds nucleotides during replication and is not a topoisomerase; the camptothecins do not act on polymerase.
Option C: Option C is incorrect because DNA gyrase is a bacterial topoisomerase targeted by fluoroquinolone antibiotics, not a target of human anticancer camptothecins.
Option E: Option E is incorrect because helicase unwinds and separates the two DNA strands and is not the camptothecin target; camptothecins act specifically on Topo I.
3. Etoposide and the anthracyclines (such as doxorubicin) act on a different topoisomerase than the camptothecins do. Which enzyme do etoposide and the anthracyclines target, and what kind of cut does that enzyme make?
A) Topoisomerase II, which makes a double-strand break in DNA and passes another DNA segment through it
B) Topoisomerase I, which makes a single-strand nick in DNA
C) Ribonucleotide reductase, which supplies the building blocks for DNA synthesis
D) Thymidylate synthase, which produces a nucleotide needed for DNA
E) Dihydrofolate reductase, which regenerates the folate cofactor used in DNA synthesis
ANSWER: A
Rationale:
Etoposide and the anthracyclines stabilize the topoisomerase II (Topo II) cleavable complex. Topo II works as a dimer that makes a transient double-strand break in one DNA duplex and passes a second intact duplex through the gap before resealing, which is how it resolves supercoiling and separates entangled daughter chromosomes. These drugs trap the enzyme after it has cut both strands, leaving persistent double-strand breaks that trigger cell death.
Option B: Option B is incorrect because topoisomerase I makes a single-strand nick and is the target of the camptothecins, not of etoposide or the anthracyclines.
Option C: Option C is incorrect because ribonucleotide reductase supplies deoxyribonucleotide building blocks and is the target of hydroxyurea, not a topoisomerase.
Option D: Option D is incorrect because thymidylate synthase produces thymidine nucleotide and is the target of fluorouracil, an antimetabolite, not a topoisomerase.
Option E: Option E is incorrect because dihydrofolate reductase regenerates reduced folate and is the target of methotrexate, again an antimetabolite mechanism rather than topoisomerase inhibition.
4. Topoisomerase-inhibiting drugs are often described as working through the "cleavable complex." What is the cleavable complex, and why does stabilizing it kill the cell?
A) It is the fully resealed, relaxed DNA released at the end of the normal reaction, and stabilizing it locks the DNA in a permanently relaxed state
B) It is a cluster of several topoisomerase enzymes bound together, and stabilizing it prevents them from finding the DNA
C) It is the intermediate in which the topoisomerase is covalently attached to the cut DNA; the drug stabilizes it so the cut cannot be resealed, leaving lethal DNA breaks
D) It is the drug itself bound to a plasma protein, and stabilizing it prolongs the drug's half-life in the bloodstream
E) It is the messenger RNA copy of the topoisomerase gene, and stabilizing it increases production of the enzyme
ANSWER: C
Rationale:
The cleavable complex is the normal but very short-lived intermediate in which the topoisomerase has cut the DNA and is covalently bonded to the cut ends, holding them in place before resealing. Topoisomerase inhibitors bind this intermediate and stabilize it, blocking the resealing step; the trapped cut becomes a permanent break when a replication or transcription complex collides with it, triggering the DNA damage response and apoptosis. The drug is therefore lethal not because it stops the enzyme outright but because it converts the enzyme into a DNA-damaging trap.
Option A: Option A is incorrect because the cleavable complex is the cut intermediate, not the final resealed relaxed DNA; the resealed product is the harmless end state, not the drug target.
Option B: Option B is incorrect because the cleavable complex involves a single enzyme bonded to DNA, not a cluster of enzymes, and the lethality comes from trapped DNA breaks rather than from keeping enzymes away from DNA.
Option D: Option D is incorrect because the cleavable complex is an enzyme-DNA intermediate inside the nucleus, not a drug-plasma protein interaction in the blood.
Option E: Option E is incorrect because the cleavable complex is not a messenger RNA transcript and stabilizing it does not increase enzyme production; it traps the enzyme on the DNA.
5. Irinotecan is given to the patient in an inactive form and must be chemically changed in the body before it can inhibit topoisomerase I. A drug that must be converted into an active form after administration is called a prodrug. For irinotecan, what is the active form that actually does the work?
A) Irinotecan is already fully active when given, so no conversion is required
B) The active form is a glucuronide conjugate produced in the kidney
C) The active form is camptothecin itself, regenerated from irinotecan in the blood
D) The active form is created only after irinotecan binds directly to topoisomerase I
E) The active form is SN-38, a metabolite produced when enzymes remove part of the irinotecan molecule
ANSWER: E
Rationale:
Irinotecan is a prodrug that carboxylesterase enzymes convert to SN-38, the metabolite roughly 100 to 1,000 times more potent as a topoisomerase I inhibitor than the parent drug. SN-38 is the species that actually stabilizes the Topo I cleavable complex and produces the antitumor effect, which is why the handling and clearance of SN-38 (not of irinotecan itself) governs both efficacy and the drug's major toxicities.
Option A: Option A is incorrect because irinotecan is specifically an inactive prodrug requiring enzymatic conversion; it is not active as administered.
Option B: Option B is incorrect because the glucuronide conjugate (SN-38G) is the inactivated, detoxified form produced by glucuronidation, the opposite of the active species.
Option C: Option C is incorrect because the active metabolite is SN-38, not regenerated parent camptothecin; irinotecan is not converted back to camptothecin in the blood.
Option D: Option D is incorrect because activation is a metabolic conversion by carboxylesterases that occurs before and independent of target binding, not something generated by the act of binding topoisomerase I.
6. Doxorubicin is one of the most effective anticancer drugs, but the total amount a patient can receive over a lifetime is strictly capped. Which toxicity is the cumulative, dose-limiting problem that imposes this lifetime ceiling?
A) Irreversible hearing loss that worsens with each dose
B) A dose-dependent, cumulative cardiomyopathy (heart muscle damage) that can progress to heart failure
C) Permanent kidney failure requiring dialysis
D) Progressive blindness from optic nerve damage
E) Cumulative liver cirrhosis from repeated dosing
ANSWER: B
Rationale:
The toxicity that caps lifetime doxorubicin exposure is a cumulative, dose-dependent cardiomyopathy. Damage to heart muscle cells accumulates silently with each dose and can progress to a dilated cardiomyopathy and heart failure once cumulative thresholds are crossed; because mature cardiomyocytes cannot regenerate, the injury is essentially irreversible, which is why total lifetime dose must be tracked and capped.
Option A: Option A is incorrect because irreversible hearing loss (ototoxicity) is characteristic of cisplatin, not doxorubicin.
Option C: Option C is incorrect because dose-limiting kidney failure is associated with cisplatin and some other agents; doxorubicin is not primarily nephrotoxic and is eliminated mainly by the liver and bile.
Option D: Option D is incorrect because progressive blindness from optic nerve damage is not a recognized dose-limiting doxorubicin toxicity.
Option E: Option E is incorrect because although doxorubicin dosing is reduced in liver dysfunction, cumulative cirrhosis is not its dose-limiting toxicity; cardiomyopathy is the toxicity that defines the lifetime ceiling.
7. Bleomycin is unusual among anticancer drugs because it causes very little bone marrow suppression. Instead, its most serious dose-limiting toxicity targets one specific organ. Which organ, and what is the toxicity?
A) The kidneys, causing acute tubular necrosis
B) The pancreas, causing drug-induced pancreatitis
C) The bone marrow, causing profound neutropenia
D) The lungs, causing pneumonitis that can progress to pulmonary fibrosis
E) The thyroid, causing irreversible hypothyroidism
ANSWER: D
Rationale:
Bleomycin's dose-limiting and potentially fatal toxicity is pulmonary: it causes a pneumonitis (inflammation of lung tissue) that can progress to pulmonary fibrosis (scarring). The lung is uniquely vulnerable because it has low levels of bleomycin hydrolase, the enzyme that inactivates the drug elsewhere in the body, so the drug persists and generates damaging reactive oxygen species in lung tissue. This is why bleomycin patients are monitored with pulmonary function testing and why cumulative dose and risk factors are tracked carefully.
Option A: Option A is incorrect because acute tubular necrosis (kidney injury) is characteristic of cisplatin, not bleomycin, although bleomycin is renally eliminated and renal impairment raises its toxicity risk.
Option B: Option B is incorrect because pancreatitis is not a recognized dose-limiting toxicity of bleomycin.
Option C: Option C is incorrect because bleomycin is notable precisely for sparing the bone marrow; minimal myelosuppression is one of its defining features.
Option E: Option E is incorrect because irreversible hypothyroidism is not a characteristic bleomycin toxicity; the lung is the target organ of concern.
8. Actinomycin D (dactinomycin) is an antitumor antibiotic that slips between DNA base pairs (intercalates). At the doses used clinically, this intercalation has one main consequence for the cell. What is the primary effect of actinomycin D?
A) It blocks RNA polymerase from moving along the DNA, shutting down transcription (the making of RNA from DNA)
B) It prevents ribosomes from translating messenger RNA into protein
C) It directly cuts both strands of DNA to produce double-strand breaks
D) It blocks the enzyme that synthesizes the lipid membrane of the cell
E) It prevents the spindle fibers from separating chromosomes during mitosis
ANSWER: A
Rationale:
Actinomycin D intercalates into DNA, preferentially at GC-rich sites, and physically blocks the progression of RNA polymerase along the template. This shuts down transcription, the copying of DNA into RNA, depriving the cell of the messenger, ribosomal, and transfer RNA it needs. Because rapidly dividing tumor cells depend heavily on continuous transcription, this is the basis of its antitumor activity.
Option B: Option B is incorrect because actinomycin D acts at the transcription step (DNA to RNA), not at translation (RNA to protein on the ribosome); blocking translation describes a different class of agents.
Option C: Option C is incorrect because actinomycin D works by intercalation and transcription blockade rather than by directly cleaving both DNA strands; direct double-strand cutting is closer to the bleomycin or topoisomerase II mechanisms.
Option D: Option D is incorrect because actinomycin D does not inhibit membrane lipid synthesis; its target is nuclear DNA-directed transcription.
Option E: Option E is incorrect because interfering with the mitotic spindle describes the vinca alkaloids and taxanes, not actinomycin D.
9. A patient receiving doxorubicin for metastatic breast cancer has accumulated a high lifetime dose but is still benefiting from the drug. A protective agent can be added to reduce the risk of doxorubicin-induced heart damage while anthracycline therapy continues. Which drug is the approved cardioprotective agent for this purpose?
A) Mesna, given to protect against bladder toxicity
B) Leucovorin, given to rescue normal cells from antifolate toxicity
C) Dexrazoxane, given to reduce anthracycline-induced cardiac injury
D) Allopurinol, given to prevent tumor lysis syndrome
E) Amifostine, given to protect against cisplatin-induced kidney injury
ANSWER: C
Rationale:
Dexrazoxane is the only agent approved specifically to reduce anthracycline-induced cardiotoxicity. It is given before doxorubicin in patients who have received a high cumulative anthracycline dose and need continued therapy, allowing some patients to keep receiving an effective drug while lowering cardiac risk.
Option A: Option A is incorrect because mesna protects the bladder from the toxic metabolite acrolein produced by cyclophosphamide and ifosfamide; it does not protect the heart.
Option B: Option B is incorrect because leucovorin rescues normal cells from methotrexate (an antifolate) and is used with fluorouracil; it has no anthracycline cardioprotective role.
Option D: Option D is incorrect because allopurinol lowers uric acid to prevent tumor lysis syndrome and does not protect the heart.
Option E: Option E is incorrect because amifostine is a cytoprotectant used mainly against cisplatin nephrotoxicity and radiation-related effects, not the approved agent for anthracycline cardioprotection.
10. The camptothecins trap topoisomerase I on the DNA after it has made a single-strand nick. By itself, a trapped single-strand nick is not necessarily fatal. What converts this trapped nick into a lethal double-strand break, and what does this tell us about which cells are most vulnerable?
A) The nick becomes lethal only after the drug is cleared, so slowly dividing cells are most affected
B) The nick is lethal immediately in all cells regardless of whether they are dividing
C) The nick becomes lethal when the cell enters a resting (non-dividing) state, sparing actively dividing cells
D) The nick becomes lethal when exposed to sunlight, so only skin cells are affected
E) The nick becomes lethal when a moving replication fork collides with the trapped complex, so cells actively copying their DNA (in S phase) are most vulnerable
ANSWER: E
Rationale:
A trapped single-strand nick becomes a lethal double-strand break when the advancing replication machinery collides with the stabilized cleavable complex during DNA synthesis. Because this collision requires active DNA replication, camptothecins are S-phase specific and preferentially kill cells that are actively copying their DNA, which is why rapidly dividing tumor cells are especially vulnerable.
Option A: Option A is incorrect because the lethal event depends on collision with a replication fork during drug exposure, not on drug clearance, and slowly dividing cells are relatively spared rather than preferentially affected.
Option B: Option B is incorrect because the trapped nick is not uniformly and immediately lethal in all cells; lethality depends on the cell undergoing DNA replication.
Option C: Option C is incorrect because entering a resting state protects cells from this mechanism rather than triggering lethality; non-dividing cells are spared.
Option D: Option D is incorrect because conversion to a lethal break depends on replication-fork collision, not on light exposure, and is not limited to skin cells.
11. During or within a few hours of an irinotecan infusion, a patient develops cramping, sweating, watery eyes, a runny nose, and diarrhea. This early reaction is caused by excess activity of the parasympathetic ("rest and digest") nervous system, which irinotecan triggers by inhibiting the enzyme that normally breaks down acetylcholine. What is the correct treatment for this early reaction?
A) High-dose loperamide started at the first loose stool
B) Atropine, given to block the excess cholinergic (parasympathetic) activity
C) Intravenous corticosteroids tapered over two weeks
D) Oral vancomycin for presumed Clostridioides difficile infection
E) Withholding all further fluids to slow the diarrhea
ANSWER: B
Rationale:
The early irinotecan syndrome is cholinergic: irinotecan inhibits acetylcholinesterase, producing a surge of parasympathetic activity with cramping, diaphoresis, lacrimation, rhinorrhea, and early diarrhea, typically during or within 24 hours of the infusion. The correct treatment is atropine, an anticholinergic that directly opposes the excess cholinergic signaling; it can also be given prophylactically in patients who reacted in prior cycles.
Option A: Option A is incorrect because high-dose loperamide is the treatment for the late diarrhea syndrome (mucosal injury after 24 hours), not for the early cholinergic reaction, and it does not address the underlying cholinergic excess.
Option C: Option C is incorrect because corticosteroids are not the treatment for cholinergic early diarrhea; the mechanism is autonomic, not inflammatory.
Option D: Option D is incorrect because this early reaction is a predictable drug effect, not an infection, so vancomycin for C. difficile is inappropriate.
Option E: Option E is incorrect because withholding fluids risks dehydration and does not treat the cholinergic mechanism; atropine is the targeted therapy.
12. A different irinotecan-related diarrhea begins more than 24 hours after the infusion. It is caused by the active metabolite SN-38 damaging the lining of the intestine directly, and it can become severe and dangerous if untreated. What is the correct treatment for this late diarrhea?
A) Atropine given immediately to block parasympathetic activity
B) Reducing fluid intake to firm up the stool
C) Intravenous magnesium replacement alone
D) High-dose loperamide, started at the first loose stool and continued until the patient is diarrhea-free
E) A single dose of a stimulant laxative to clear the irritant
ANSWER: D
Rationale:
Late irinotecan diarrhea results from direct mucosal toxicity caused by SN-38 in the intestinal lumen and is treated with high-dose loperamide started at the first loose stool and continued until the patient has been diarrhea-free for a sustained period. Patients must be counseled on this protocol in advance because untreated late diarrhea, especially combined with neutropenia, can be life-threatening.
Option A: Option A is incorrect because atropine treats the early cholinergic syndrome; it does not address late mucosal-injury diarrhea.
Option B: Option B is incorrect because reducing fluids risks dangerous dehydration in a patient who may already be losing large volumes; aggressive hydration plus loperamide is appropriate.
Option C: Option C is incorrect because magnesium replacement alone does not treat the diarrhea mechanism, though electrolytes may need correction as supportive care.
Option E: Option E is incorrect because a stimulant laxative would worsen diarrhea; the goal is to slow gut motility with loperamide, not to stimulate it.
13. Before starting high-dose irinotecan, some patients are tested for a genetic variant called UGT1A1*28. This variant reduces the activity of the liver enzyme (UGT1A1) that normally attaches a sugar group to SN-38 to inactivate it for excretion. Why does carrying two copies of this variant matter for irinotecan dosing?
A) The active metabolite SN-38 is cleared more slowly and accumulates, raising the risk of severe neutropenia and diarrhea, so a lower starting dose may be needed
B) Irinotecan cannot be converted to SN-38 at all, so the drug is completely ineffective
C) SN-38 is cleared faster than normal, so higher doses are required for any effect
D) The variant only affects the early cholinergic diarrhea and has no impact on blood counts
E) The variant increases conversion of irinotecan to SN-38, producing more drug than intended
ANSWER: A
Rationale:
UGT1A1 inactivates SN-38 by glucuronidation. The UGT1A1*28 variant lowers the enzyme's activity, so patients homozygous for it clear SN-38 more slowly; the metabolite accumulates to higher levels and persists longer, increasing the risk of severe neutropenia and grade 3 to 4 diarrhea at standard doses. This is why genotyping can guide a reduced starting dose.
Option B: Option B is incorrect because the variant affects SN-38 inactivation (clearance), not the carboxylesterase activation step; SN-38 is still formed, and the drug is not rendered ineffective.
Option C: Option C is incorrect because reduced enzyme activity slows SN-38 clearance rather than speeding it, so the metabolite builds up rather than requiring higher doses.
Option D: Option D is incorrect because the variant affects systemic SN-38 exposure and therefore marrow and gut toxicity, not just the early cholinergic syndrome.
Option E: Option E is incorrect because UGT1A1 inactivates SN-38 and does not perform the activation step; the variant does not increase SN-38 production but impairs its removal.
14. One major mechanism of doxorubicin heart damage is the generation of reactive oxygen species (highly reactive, damaging oxygen-derived molecules) inside heart muscle cells. Why are cardiomyocytes (heart muscle cells) especially vulnerable to this oxidative injury compared with many other cell types?
A) Cardiomyocytes concentrate the drug to far higher levels than any other tissue
B) Cardiomyocytes lack mitochondria and cannot produce energy once injured
C) Cardiomyocytes have relatively low levels of protective antioxidant enzymes and are postmitotic, so they cannot easily replace damaged cells by dividing
D) Cardiomyocytes divide rapidly, so the drug preferentially kills them during replication
E) Cardiomyocytes convert doxorubicin into a second, more cardiotoxic anticancer drug
ANSWER: C
Rationale:
Cardiomyocytes are particularly susceptible to anthracycline oxidative injury because they express relatively low levels of antioxidant enzymes (such as catalase and glutathione peroxidase) compared with cells like hepatocytes, and because they are postmitotic, meaning they generally cannot divide to replace cells lost to injury. Damage therefore accumulates silently and is effectively irreversible, which underlies the cumulative dose ceiling.
Option A: Option A is incorrect because the vulnerability arises from weak antioxidant defenses and the inability to regenerate, not from cardiomyocytes concentrating the drug far above other tissues.
Option B: Option B is incorrect because cardiomyocytes are in fact rich in mitochondria to support continuous contraction; that mitochondrial density is part of what makes them vulnerable, not an absence of mitochondria.
Option D: Option D is incorrect because cardiomyocytes are postmitotic and do not divide rapidly; the injury is not a replication-dependent kill as in dividing tumor cells.
Option E: Option E is incorrect because cardiomyocytes do not transform doxorubicin into a separate, more cardiotoxic anticancer drug; the toxicity comes from reactive oxygen species and related mechanisms.
15. A patient who previously received bleomycin is scheduled for surgery under general anesthesia. The anesthesia team should be specifically informed of the bleomycin history. What is the danger, and what is the key precaution?
A) Bleomycin reacts with anesthetic gases to form a toxic compound, so only intravenous anesthetics may be used
B) Bleomycin lowers the seizure threshold, so the patient must be pretreated with anticonvulsants
C) Bleomycin causes malignant hyperthermia, so dantrolene must be on hand
D) Bleomycin prolongs the action of muscle relaxants, so their doses must be halved
E) High inspired oxygen can trigger severe, sometimes fatal lung injury in bleomycin-exposed patients, so the oxygen concentration should be kept as low as safely tolerable
ANSWER: E
Rationale:
Bleomycin sensitizes lung tissue so that high inspired oxygen concentrations can trigger acute, sometimes fatal lung injury (an ARDS-like picture, where ARDS stands for acute respiratory distress syndrome). The key precaution is to keep the fraction of inspired oxygen as low as is consistent with adequate oxygen saturation during and after anesthesia, and to alert the anesthesia team to any prior bleomycin exposure. There is no firmly established safe interval after which this risk disappears.
Option A: Option A is incorrect because the danger is high inspired oxygen, not a chemical reaction with anesthetic gases, so the precaution concerns oxygen concentration rather than banning inhaled anesthetics.
Option B: Option B is incorrect because bleomycin is not characterized by lowering the seizure threshold and does not require anticonvulsant pretreatment.
Option C: Option C is incorrect because malignant hyperthermia is a pharmacogenetic reaction to certain anesthetics and succinylcholine, unrelated to bleomycin.
Option D: Option D is incorrect because bleomycin does not prolong neuromuscular blocker action; the relevant interaction is with inspired oxygen, not muscle relaxant dosing.
16. Earlier questions established that camptothecins act on topoisomerase I, while etoposide and the anthracyclines act on topoisomerase II. One important late complication is treatment-related acute myeloid leukemia (a secondary blood cancer caused by the chemotherapy itself, abbreviated AML). Based on the mechanisms covered, which agent carries a recognized risk of this secondary leukemia?
A) Topotecan, because topoisomerase I inhibition directly mutates blood-forming cells
B) Etoposide, because topoisomerase II poisoning is linked to treatment-related AML (often with a characteristic gene rearrangement)
C) Irinotecan, because its active metabolite SN-38 is concentrated in bone marrow stem cells
D) Bleomycin, because its lung toxicity extends to the bone marrow
E) Actinomycin D, because blocking transcription permanently mutates the leukemia genes
ANSWER: B
Rationale:
Treatment-related AML is specifically linked to the topoisomerase II poisons, and etoposide is the classic example; the double-strand breaks generated at Topo II can produce characteristic gene rearrangements (classically involving the MLL gene) that drive a secondary leukemia with a relatively short latency. The camptothecins (Topo I inhibitors) do not carry this same recognized secondary-leukemia risk.
Option A: Option A is incorrect because topotecan is a Topo I inhibitor and does not carry the topoisomerase II-associated secondary AML risk described here.
Option C: Option C is incorrect because irinotecan is also a Topo I agent; its dose-limiting problems are diarrhea and neutropenia, not a recognized secondary AML signature.
Option D: Option D is incorrect because bleomycin's hallmark toxicity is pulmonary, and it is notably marrow-sparing, so it is not the agent associated with treatment-related AML.
Option E: Option E is incorrect because actinomycin D acts by blocking transcription and is not the agent classically linked to topoisomerase II-type secondary leukemia.
17. Packaging doxorubicin inside tiny fat-based particles (liposomal doxorubicin) changes how the drug distributes in the body and shifts its side-effect profile. Compared with conventional doxorubicin, the heart toxicity and bone marrow suppression are reduced, but a new side effect becomes dose-limiting. Which new toxicity is characteristic of liposomal doxorubicin?
A) Profound, irreversible hearing loss
B) Acute kidney failure requiring dialysis
C) Severe peripheral neuropathy with foot drop
D) Hand-foot syndrome (palmar-plantar erythrodysesthesia) — painful redness, swelling, and peeling of the palms and soles
E) Acute hemorrhagic cystitis (bladder bleeding)
ANSWER: D
Rationale:
Liposomal encapsulation prolongs circulation and changes tissue distribution, reducing cardiotoxicity and myelosuppression relative to conventional doxorubicin, but it makes hand-foot syndrome (palmar-plantar erythrodysesthesia) the prominent dose-limiting toxicity, along with mucositis. Hand-foot syndrome presents as painful redness, swelling, and desquamation of the palms and soles and is managed by dose reduction and cycle delay.
Option A: Option A is incorrect because irreversible hearing loss is a cisplatin toxicity, not a feature of liposomal doxorubicin.
Option B: Option B is incorrect because dialysis-requiring renal failure is characteristic of cisplatin; doxorubicin formulations are not primarily nephrotoxic.
Option C: Option C is incorrect because severe peripheral neuropathy is typical of the vinca alkaloids and taxanes, not liposomal doxorubicin.
Option E: Option E is incorrect because hemorrhagic cystitis is caused by cyclophosphamide and ifosfamide (via acrolein), not by liposomal doxorubicin.
18. A patient who received doxorubicin for breast cancer several years ago now needs anthracycline-containing treatment for a new cancer. Before prescribing, the oncologist adds up the patient's entire lifetime anthracycline exposure. Why is this total, rather than just the planned new dose, the critical number?
A) Anthracycline heart damage is cumulative and largely irreversible, so the risk of heart failure depends on the total lifetime dose across all prior and current treatment combined
B) The prior dose has fully cleared the body, so only the new dose determines the risk
C) Each new cancer resets the heart's tolerance, so prior exposure no longer counts
D) The total dose determines only the antitumor effect, not the cardiac risk
E) Lifetime totals matter only for kidney toxicity, not for the heart
ANSWER: A
Rationale:
Anthracycline cardiomyopathy reflects cumulative, largely irreversible injury to cardiomyocytes, so the risk of heart failure is governed by total lifetime exposure rather than by any single course. Prior doses must be counted (often converted to doxorubicin-equivalents) and added to planned dosing, because a patient may already have used a large fraction of the safe lifetime ceiling before the new treatment even begins.
Option B: Option B is incorrect because clearance of the drug from plasma does not undo the accumulated cardiomyocyte injury; the damage persists even after the drug is gone.
Option C: Option C is incorrect because the heart does not reset its tolerance with a new diagnosis; prior cumulative injury still counts.
Option D: Option D is incorrect because cumulative dose is precisely what drives cardiac risk, not merely antitumor effect.
Option E: Option E is incorrect because the lifetime-total concern for anthracyclines is cardiac, not renal; anthracyclines are not primarily nephrotoxic.
19. Question 9 introduced dexrazoxane as the agent used to protect the heart during anthracycline therapy. Thinking about how doxorubicin damages cardiomyocytes, what is the main way dexrazoxane provides that protection?
A) It scavenges anthracycline molecules directly in the bloodstream before they reach the heart
B) It speeds the kidney's removal of doxorubicin so less reaches cardiac tissue
C) It binds (chelates) intracellular iron, preventing the iron-dependent formation of reactive oxygen species that injure cardiomyocytes
D) It stimulates the heart to grow new cardiomyocytes to replace damaged ones
E) It blocks doxorubicin from entering tumor cells, which indirectly protects the heart
ANSWER: C
Rationale:
A central driver of anthracycline cardiac injury is the iron-dependent generation of reactive oxygen species inside cardiomyocytes. Dexrazoxane is taken up by cells and converted to an iron-chelating form that binds intracellular free iron, removing the iron needed to catalyze reactive oxygen species formation and thereby reducing oxidative damage to the heart. Its protection is therefore mechanistic and intracellular, not a simple drug-mopping action in the blood.
Option A: Option A is incorrect because dexrazoxane does not chemically neutralize anthracycline molecules circulating in plasma; it acts inside cells on iron chemistry.
Option B: Option B is incorrect because dexrazoxane does not protect by accelerating renal clearance of doxorubicin.
Option D: Option D is incorrect because cardiomyocytes are postmitotic and dexrazoxane does not regenerate lost heart muscle cells; it prevents injury rather than replacing cells.
Option E: Option E is incorrect because dexrazoxane does not work by blocking doxorubicin entry into tumor cells, and importantly it is not intended to reduce antitumor efficacy.
20. Etoposide shows what pharmacologists call schedule dependency: giving the same total dose in different ways changes how well it works. For etoposide, which dosing approach generally produces a better antitumor effect?
A) A single large intravenous bolus, because a high peak concentration maximizes cell kill
B) Alternating the drug with a one-month gap between every dose
C) Giving the entire course as one oral dose on a single day
D) Restricting administration to once every several weeks at very high dose
E) Spreading the same total dose over several days of lower-dose exposure, which sustains drug levels and improves the response
ANSWER: E
Rationale:
Etoposide is schedule-dependent: dividing the same total dose into prolonged lower-dose exposure (for example, daily dosing over several days) sustains drug concentrations across more of the cell cycle window in which topoisomerase II is vulnerable, and produces higher response rates than the same dose given as a single large bolus. This is why divided or prolonged schedules are favored in settings such as small cell lung cancer.
Option A: Option A is incorrect because a single large bolus, despite its high peak, is generally less effective than divided dosing for etoposide; peak concentration is not what drives its effect.
Option B: Option B is incorrect because inserting long month-long gaps between doses would not sustain effective exposure and is not the favorable schedule.
Option C: Option C is incorrect because compressing the whole course into one oral dose sacrifices the sustained exposure that underlies etoposide's schedule dependency.
Option D: Option D is incorrect because infrequent very-high-dose administration is the opposite of the prolonged lower-dose approach that improves etoposide's antitumor effect.
21. A patient develops watery diarrhea, cramping, sweating, and teary eyes about 15 minutes into an irinotecan infusion. A trainee reaches for high-dose loperamide. Using the distinction between the two irinotecan diarrhea syndromes, what is the correct action?
A) Give the loperamide as planned, since loperamide treats all irinotecan diarrhea
B) Recognize this as the early cholinergic syndrome and treat with atropine, not loperamide
C) Stop irinotecan permanently, since any infusion-time diarrhea is an allergic reaction
D) Treat with oral vancomycin for presumed infection
E) Give a stimulant laxative to flush the irritant metabolite out faster
ANSWER: B
Rationale:
The timing and the cholinergic features (cramping, diaphoresis, lacrimation occurring during the infusion) identify this as the early cholinergic syndrome, which is driven by acetylcholinesterase inhibition and is treated with atropine. Loperamide is the treatment for the late mucosal-injury diarrhea that begins more than 24 hours after the infusion, so it is the wrong choice here. Distinguishing the two syndromes by timing and accompanying symptoms is what selects the correct drug.
Option A: Option A is incorrect because loperamide does not treat the early cholinergic syndrome; matching drug to syndrome is the whole point.
Option C: Option C is incorrect because the early cholinergic reaction is an expected, treatable pharmacologic effect, not an allergy mandating permanent discontinuation.
Option D: Option D is incorrect because this is a predictable drug effect rather than an infection, so vancomycin is inappropriate.
Option E: Option E is incorrect because a stimulant laxative would worsen the diarrhea and does not address the cholinergic mechanism, which atropine targets.
22. This set has covered several drugs whose dose-limiting toxicities differ by class. Which of the following correctly matches each drug to its characteristic dose-limiting toxicity?
E) Doxorubicin causes bone marrow suppression as its lifetime-limiting toxicity; bleomycin causes kidney failure; topotecan causes cardiomyopathy
ANSWER: D
Rationale:
Each class has a signature dose-limiting toxicity. Topotecan, a topoisomerase I inhibitor, is dose-limited by myelosuppression (especially neutropenia). Doxorubicin, an anthracycline, is limited over a lifetime by cumulative cardiomyopathy. Bleomycin is limited by pulmonary toxicity (pneumonitis progressing to fibrosis). Option D pairs each drug with the correct toxicity.
Option A: Option A is incorrect because it swaps the bleomycin and doxorubicin toxicities (bleomycin is pulmonary, doxorubicin is cardiac) and misassigns topotecan.
Option B: Option B is incorrect because it again reverses the lung and heart toxicities of bleomycin and doxorubicin and wrongly assigns hearing loss to topotecan.
Option C: Option C is incorrect because bleomycin is marrow-sparing rather than marrow-limited, topotecan is not lung-toxic, and doxorubicin does not cause bladder bleeding (that is cyclophosphamide).
Option E: Option E is incorrect because doxorubicin's lifetime-limiting toxicity is cardiomyopathy rather than marrow suppression, bleomycin is not primarily nephrotoxic, and topotecan is not cardiotoxic.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.